Osteoarthritis Gene Therapy Market Analysis

The market is segmented by drug type into NSAIDs, corticosteroids, viscosupplementation agents, and analgesics, out of which, the viscosupplementation agent segment is anticipated to hold the largest share in the global osteoarthritis gene therapy market during the forecast period, on account of the high prevalence of knee osteoarthritis in the global population in recent decades. The rising cases of knee osteoarthritis are accounted to the significant change in the lifestyle such as spending more time on PCs resulting in knee joint cartilage wearing out over time. For instance, it was observed that approximately 200 people out of 10,000 suffer from knee osteoarthritis every year globally.

Our in-depth analysis of the global market includes the following segments:

By Type	NSAIDs Aspirin Diclofenac Ibuprofen Naproxen Corticosteroids Viscosupplementation Agents Analgesics Acetaminophen Duloxetine
By Purchasing Pattern	Over-the-Counter Prescription
By Distribution Channel	Hospital Pharmacies Online
By End-User	Clinic Hospital Nursing Home

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of osteoarthritis gene therapy is estimated at USD 8.61 billion.

Osteoarthritis Gene Therapy Market size was valued at USD 8.07 billion in 2024 and is likely to cross USD 21.68 billion by 2037, expanding at more than 7.9% CAGR during the forecast period i.e., between 2025-2037.

Europe industry is estimated to dominate majority revenue share by 2037, on the back of increasing geriatric population with osteoarthritis disease.

The major players in the market are Sanofi-aventis Groupe, Horizon Therapeutics plc, Hanmi Pharm. Co., Ltd., ALMATICA PHARMA LLC., Assertio Holdings, Inc., Flexion Therapeutic, Inc., Zimmer Biomet Holdings, Inc., Pfizer Inc., and others.

Osteoarthritis Gene Therapy Market Analysis